PT-141 Protocol: Complete Cycling & Dosing Guide

Overview

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that works centrally in the brain to enhance sexual motivation and arousal through dopaminergic pathway activation. Unlike phosphodiesterase-5 inhibitors such as sildenafil that work on vascular smooth muscle, PT-141 targets the hypothalamus and limbic system to increase endogenous sexual desire signaling.

The compound is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women but is widely used off-label by both men and women for sexual enhancement and arousal. It also demonstrates modest efficacy for reducing appetite and body weight through melanocortin-4 receptor (MC4R) agonism, though evidence remains limited to a single 16-day Phase 1 trial in obese women.

PT-141 is available as an injectable peptide or intranasal formulation. The injection route is more common among research peptide users due to better dose precision and consistency. Standard dosing ranges from 1,000–2,000 micrograms (1–2 mg) as needed, with a maximum frequency of once per 24 hours.

The most common adverse effect is nausea, affecting up to 40% of users with onset 30–60 minutes post-administration. Facial flushing, transient hyperpigmentation with repeated use, and modest blood pressure elevation (6–10 mmHg systolic) are also reported. The blood pressure effect lasts approximately 12 hours and makes PT-141 contraindicated in individuals with uncontrolled hypertension or significant cardiovascular risk.

Standard Protocol

Basic As-Needed Protocol

Dose: 1.0–1.5 mg injected subcutaneously or intramuscularly, or 1.0–2.0 mg intranasally

Frequency: As needed, no more than once per 24 hours

Duration: No defined maximum; PT-141 is used as an acute sexual performance enhancer rather than a continuous daily compound

Timing: Administer 30–60 minutes before anticipated sexual activity for optimal effect

Route Preference: Subcutaneous injection in the abdomen or upper thigh offers the most reliable dosing precision and fastest onset (15–30 minutes). Intranasal administration is more convenient but shows greater inter-individual variability and higher nausea rates.

Dose Escalation Strategy

Begin with 0.75–1.0 mg to assess individual tolerance and response. Most users experience meaningful arousal enhancement at 1.0–1.5 mg. Those with minimal response after 48 hours of use may increase to 1.5–2.0 mg. Doses above 2.0 mg provide no additional efficacy and increase adverse effect risk.

Do not escalate dose on the same day; assess response over at least two separate administrations before increasing.

Storage and Reconstitution

If purchasing freeze-dried powder, reconstitute with bacteriostatic water at a concentration of 10 mg/mL (standard for peptide vendors). This yields 100 units = 100 mcg on a standard 100-unit insulin syringe.

Store reconstituted solution at 2–8°C (refrigerated) for up to 30 days, or at room temperature for up to 14 days if unopened. Protect from light. Pre-mixed solutions sold by vendors should be stored according to label instructions, typically refrigerated.

Goal-Specific Protocols

Sexual Enhancement Protocol (Women)

Objective: Increase sexual desire, arousal, and satisfaction in premenopausal women with or without diagnosed hypoactive sexual desire disorder

Dose: 1.0–1.5 mg subcutaneously

Frequency: 1–3 times per week as needed before planned sexual activity, or daily if treating persistent HSDD (maximum once per 24 hours)

Expected Timeline: Effects begin 15–30 minutes post-injection; peak arousal occurs 45–90 minutes after administration and persists 3–4 hours

Efficacy Markers: Increased vaginal lubrication, subjective desire scores, frequency of satisfying sexual events (expect +0.5–0.7 additional satisfying events per month with consistent use)

Nausea Management: Nausea onset typically occurs 30–60 minutes post-dose. Take 500 mg ginger root supplement 20 minutes before injection, or use over-the-counter antihistamines (diphenhydramine 25–50 mg) 30 minutes prior. Eating a light meal beforehand reduces nausea severity.

Cycle Example for HSDD Treatment: 1.0 mg twice weekly for 4 weeks; assess response; increase to 1.5 mg twice weekly if needed for weeks 5–8. Take a 2-week break, then resume 1.0 mg twice weekly.

Sexual Enhancement Protocol (Men)

Objective: Enhance sexual motivation, arousal, and erectile function in men with psychogenic or combined erectile dysfunction

Dose: 1.0–2.0 mg subcutaneously; men often require higher doses than women for equivalent effect

Frequency: As needed 30–60 minutes before sexual activity, no more than daily

Expected Timeline: Onset 15–30 minutes; peak effects 45–90 minutes; duration 3–4 hours

Efficacy Markers: Increased genital arousal, spontaneous erections, enhanced subjective sexual desire and pleasure, improved erectile rigidity and duration

Stacking Consideration: PT-141 works synergistically with PDE5 inhibitors (sildenafil, tadalafil) due to complementary mechanisms—PT-141 enhances central motivation while PDE5i improves vascular response. Use 1.0 mg PT-141 + 50 mg sildenafil or equivalent for enhanced effect in men with both central and vascular dysfunction. Start with this combination only if tolerated well to each compound separately.

Cycle Example: 1.0–1.5 mg as needed (2–4 times weekly) for 8–12 weeks; assess response and sexual satisfaction. Maintain as needed indefinitely; no tolerance develops with this intermittent dosing pattern.

Appetite Suppression and Weight Loss Protocol

Objective: Reduce caloric intake and body weight through MC4R-mediated appetite suppression

Dose: 1.0 mg subcutaneously

Frequency: Once daily in the morning, or once daily 30 minutes before the largest meal

Duration: 12–16 weeks on, 4 weeks off

Expected Outcome: Modest appetite reduction (~300–400 kcal/day reduction based on limited Phase 1 data), potentially 0.8–1.3 kg body weight reduction over 16 days with maintained caloric deficit

Evidence Caveat: Efficacy data comes from a single small Phase 1 trial lasting 16 days. Longer-term efficacy and optimal dosing remain unestablished. PT-141 is not approved for weight loss and this represents off-label use.

Cycle Example: Week 1–2: 0.75 mg daily in morning to assess GI tolerance; Week 3–12: 1.0 mg daily in morning; Week 13–16: continue 1.0 mg daily; Week 17–20: take 4-week break; restart cycle if desired for another 12–16 weeks.

Monitoring: Track hunger scores subjectively and body weight weekly. If appetite suppression diminishes after 6 weeks, take a 7-day break before resuming. Expect less pronounced effect after repeated cycles due to central nervous system adaptation.

How to Administer Step-by-Step

Subcutaneous Injection Method

1. Prepare supplies: Reconstituted PT-141 solution, 100-unit insulin syringe, 28-30 gauge needle, alcohol wipes, and a sharps container.

2. Draw dose: For a 10 mg/mL solution, 100 units on the syringe = 1 mg. Draw to your target dose (e.g., 100–200 units for 1–2 mg).

3. Select injection site: Abdomen (2 inches below navel, avoiding the midline), upper thigh (lateral quadriceps), or upper arm (back of triceps). Rotate sites daily to prevent lipohypertrophy.

4. Sanitize: Wipe injection site with alcohol; allow 10 seconds to dry.

5. Inject: Pinch skin fold slightly, insert needle at a 45–90 degree angle, and slowly depress plunger over 3–5 seconds.

6. Withdraw: Remove needle, apply light pressure with sterile gauze for 10 seconds.

7. Timing: Administer 30–60 minutes before anticipated sexual activity, or in the morning for appetite suppression protocols.

Intranasal Administration Method

1. Prepare: Ensure nasal passages are clear; gently blow nose but do not sniff forcefully.

2. Dose: 1.0–2.0 mg per administration; many commercially available nasal formulations are pre-dosed in spray bottles.

3. Administer: Tilt head slightly back, insert nozzle into one nostril, and depress firmly. Repeat in opposite nostril if full dose spans both sides.

4. Allow absorption: Keep head tilted back for 10–15 seconds; do not sniff or swallow immediately.

5. Timing: Use 30–60 minutes before sexual activity. Onset may be slightly slower than injection (20–40 minutes).

Note: Intranasal administration shows higher rates of nausea (up to 45%) compared to injection, and bioavailability is more variable between individuals.

Cycle Example: Week-by-Week Schedule

Sexual Enhancement 8-Week Cycle (Women)

Week 1–2: 1.0 mg subcutaneously every 2–3 days before planned sexual activity; assess tolerance and response; track nausea incidence and severity

Week 3–4: 1.0 mg twice per week if response is good; increase to 1.25 mg if minimal response or sexual satisfaction remains low

Week 5–6: Maintain effective dose (1.0–1.5 mg twice per week); nausea typically resolves or diminishes by week 4 as the body acclimates

Week 7–8: Continue twice-weekly dosing; prepare for cycle break

Week 9–10: Complete break; no PT-141 administration; assess baseline sexual function without compound

Week 11–12: Resume at previous effective dose (1.0–1.5 mg twice per week) for another 8-week block if sustained benefit is desired

Sexual Enhancement 12-Week Cycle (Men)

Week 1: 1.0 mg as needed (1–2 times weekly) before sexual activity; test tolerance

Week 2–4: 1.0 mg as needed (2–3 times weekly); or escalate to 1.5 mg if minimal sexual motivation increase

Week 5–8: Maintain effective dose (1.0–1.5 mg) with frequency adjusted to sexual activity schedule (typically 2–4 times weekly); monitor for continued efficacy

Week 9–12: Continue as needed; if efficacy declines, consider 1-week break before resuming

Week 13 onward: Use indefinitely as needed; tolerance does not typically develop with this intermittent dosing pattern

What to Expect: Timeline of Effects

Immediate Effects (15–30 minutes post-injection)

• Mild facial warmth and flushing (may affect 30–50% of users)
• Early-stage genital arousal in some individuals
• Possible nausea onset (typically 30–60 minutes, peaks 60–90 minutes)

Early Effects (30–90 minutes post-injection)

• Peak facial flushing and skin warmth
• Marked increase in sexual motivation and spontaneous thoughts of sex
• Enhanced genital arousal; for women, increased vaginal lubrication; for men, spontaneous or semi-spontaneous erections
• Possible mild headache (associated with small blood pressure elevation)
• Nausea may peak; often resolves within 60–90 minutes even without intervention

Peak Effects (90 minutes to 3 hours post-injection)

• Maximum sexual arousal and desire
• Enhanced sensitivity to sexual stimuli
• Sustained erectile response in men
• Significantly increased pleasure and satisfaction during sexual activity
• Flushing typically resolves by 2–3 hours

Late Effects (3–4 hours post-injection)

• Gradual decline in arousal and sexual motivation
• Return to baseline by 4–6 hours for most users
• Blood pressure elevation persists until approximately 12 hours post-administration but causes no subjective symptoms

24-Hour Checkpoint

• Complete return to baseline sexual motivation
• No residual nausea or flushing
• Safe to re-dose if desired (maximum frequency once per 24 hours)

Signs It's Working

In Women:

• Spontaneous sexual thoughts between administrations
• Increased vaginal lubrication without direct genital stimulation
• Higher frequency of satisfying sexual events (expect +0.5–0.7 per month)
• Subjective improvement in sexual pleasure and arousal during activity
• Reduced sexual distress and increased sexual satisfaction scores

In Men:

• Spontaneous morning erections and increased genital arousal
• Enhanced sensitivity to sexual stimuli (visual, tactile, auditory)
• Stronger and more sustained erectile response
• Increased sexual motivation and initiation
• Greater pleasure intensity during sexual activity

General Indicator: Efficacy is evident within 2–3 administrations if PT-141 is working for you. If no subjective increase in sexual motivation or arousal occurs after three separate doses, it is unlikely to be effective, and discontinuation is reasonable.

When to Adjust

Increase dose if:

• Three or more administrations at current dose produce minimal sexual arousal or motivation increase
• Sexual satisfaction remains unchanged despite compound use
• Nausea is minimal or absent and can be easily managed

Decrease dose if:

• Nausea is severe enough to interfere with sexual activity or quality of life
• Blood pressure elevation (monitor with home BP cuff if possible) exceeds 15 mmHg systolic
• Facial flushing is extreme or distressing

Discontinue if:

• Persistent headaches develop that do not resolve with standard analgesics
• Cardiovascular symptoms (chest discomfort, palpitations, dyspnea) occur
• No efficacy is observed after 4–6 administrations
• Adverse effects consistently outweigh perceived benefits

Common Protocol Mistakes

Mistake 1: Daily Use Expecting Cumulative Benefit

PT-141 is an as-needed performance enhancer, not a daily supplement. Daily use does not enhance baseline sexual function on non-use days and increases adverse effect cumulative risk and cost. Use 2–4 times weekly maximum for best risk-benefit ratio.

Mistake 2: Overdosing to Overcome Nausea

Users often increase dose thinking PT-141 "isn't working," when in fact nausea is reducing the perceived efficacy. Nausea peaks 60–90 minutes post-administration. Manage with ginger, antihistamines, or food before escalating dose. Most nausea resolves or becomes tolerable by week 3–4.

Mistake 3: Expecting Immediate Erection Response (Men)

PT-141 enhances arousal and motivation centrally; it does not cause mechanical erections like PDE5 inhibitors. Erection quality improves with sexual stimulation and psychological arousal, not passively. If expecting passive tumescence, PT-141 is not the right tool.

Mistake 4: Administering Too Close to Sexual Activity

Most users expect effects at 15 minutes, but peak arousal occurs 60–90 minutes post-injection. Administer 45–75 minutes before anticipated sexual activity, not 5–10 minutes prior. Intranasal forms work slightly faster (20–40 minutes) but remain unpredictable.

Mistake 5: Inadequate Nausea Prevention

Users often avoid nausea management and simply tolerate the discomfort. Pre-medication with 500 mg ginger root or 25–50 mg diphenhydramine 20–30 minutes before injection reduces nausea by 50–70%. Eating a light meal 30–60 minutes before injection also helps significantly.

Mistake 6: No Cycle Breaks

Continuous use (even at 2–3 times weekly) may lead to central nervous system adaptation and reduced efficacy over 8–12 weeks. Take 2–4 week breaks every 8–12 weeks of use to restore responsiveness.

Mistake 7: Failing to Rotate Injection Sites

Repeated injection at the same location causes lipohypertrophy (localized fat accumulation) and reduces absorption consistency. Rotate between abdomen, thighs, and upper arms daily.

How to Stack with Other Compounds

PT-141 + Sildenafil (Viagra) or Tadalafil (Cialis)

**